Anna is from England and recently finished her undergraduate degree. She has an interest in medicine and enjoys writing. In her spare time she likes to cook, hike, and hang out with cats.
Medical Research Network (MRN) is an organisation that specialises in the conduct of clinical trial visits in the patient’s home and supporting clinical trial sites with nursing resources. MRN aims…
Continue ReadingMedical Research Network is Improving Clinical Trials
The biotechnology company Bloom Science has found that the ketogenic diet can be an effective treatment for epilepsy due to its effects on gut bacteria. Bloom Science is planning on…
Continue ReadingResearchers Are Investigating Epilepsy Treatments Based on Gut Bacteria
Researchers from the UK have developed a new test for oesophageal cancer. The full article can be found here, at ABC News. Oesophageal cancer is a form of cancer estimated…
Continue ReadingA New Breath Test Is Being Developed to Diagnose Esophageal Cancer
Dicerna Pharmaceuticals has dosed the first patient with primary hyperoxaluria in Group B of a clinical trial of the investigational drug DCR-PHXC. Dicerna has also announced that DCR-PHXC has just…
Continue ReadingA Study of an Investigational Drug For Primary Hyperoxaluria Has Dosed its First Patient
Researchers have found that inhibiting an enzyme called heparanase can significantly reduce the growth of mesothelioma in mouse models. The full article can be found here, at the American Technion…
Continue ReadingAn Enzyme Has Been Found to Significantly Reduce Mesothelioma Growth in Mice
A recently published study has found that a protein the in blood, called CC16, can predict lung disease progression in patients with systemic sclerosis. High levels of the protein are…
Continue ReadingA Protein Has Been Found to Predict Lung Function Decline in Patients with Systemic Sclerosis
The information in this article is based on the HAE UK and the US Hereditary Angioedema Association websites. Hereditary angioedema (HAE) is a condition that affects about one in every…
Continue ReadingEverything You Need to Know About Three Types of Hereditary Angioedema
The Investigational New Drug Application for the experimental drug CTX001 for treating sickle cell disease has been put on clinical hold, announced Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics. This hold…
Continue ReadingThe FDA has placed an Investigational Drug For Sickle Cell Disease on Clinical Hold
Pfizer has announced that the medicine Xalkori (crizotinib) has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for two potential treatment uses. The full article can be…
Continue ReadingThe FDA Has Awarded Breakthrough Therapy Designation to an Experimental Drug for Treating Some Forms of Lung Cancer and Anaplastic Large Cell Lymphoma
A study has discovered a mechanism involved in amyotrophic lateral sclerosis (ALS). The researchers hope that this new information could contribute to finding a treatment for the condition. The full…
Continue ReadingResearchers Have Discovered a Mechanism Underlying ALS
A recent study by researchers in the US has linked Lynch syndrome to several more forms of cancer. Previously, Lynch syndrome has mainly been associated with colorectal and endometrial cancers,…
Continue ReadingLynch Syndrome Is Linked to More Types of Cancer Than Previously Thought
The results of a Phase 1 clinical trial of the experimental drug ivosidenib, led by researchers at The University of Texas MD Anderson Cancer Center, have been published in the…
Continue ReadingAn Experimental Drug May Be Effective For Acute Myeloid Leukemia with a Gene Alteration
A primary immunodeficiency report, published in the journal Clinical and Experimental Immunology, examines medical care for primary immunodeficiency patients in the UK. The publication of the report coincides with the…
Continue ReadingA Report on UK Patients with Primary Immunodeficiency Hopes to Inform Medical Professionals About the Conditions
The biopharmaceutical company Complexa, Inc., has announced that the first patient has been dosed on the Phase 2 clinical trial FIRSTx. FIRSTx is a study of the experimental drug CXA-10…
Continue ReadingThe First Patient Has Been Dosed in a Clinical Trial of a Drug to Treat FSGS
Loxo Oncology has announced that the US Food and Drug Administration (FDA) has granted the drug larotrectinib Priority Review, and accepted a New Drug Application (NDA) for it. These applications…
Continue ReadingA Cancer Drug Has Been Granted a New Drug Application by the FDA
Researchers at the Massachusetts General Hospital Research Institute and the Georgia Institute of Technology are investigating a medication currently approved to treat a type of multiple sclerosis as a possible…
Continue ReadingResearch Suggests a Multiple Sclerosis Treatment May Also Benefit Mucolipidosis IV
Researchers have carried out a study into the genetic mechanisms involved in hereditary angioedema acute attacks. They found that two genes, called uPAR and ADM, had a particularly strong influence.…
Continue ReadingScientists Have Identified Genes Involved in Hereditary Angioedema Acute Attacks
Research into possible facial creams containing the medicine rapamycin have found that they are effective for reducing facial tumours in people with tuberous sclerosis complex. The full article can be…
Continue ReadingResearch Shows That a Facial Cream Containing Rapamycin Could Improve Facial Tumours Linked to Tuberous Sclerosis Complex
A Phase II trial of the experimental treatment SurVaxM, under development by the biotechnology company MimiVax LLC, has produced encouraging interim results for treating patients with newly diagnosed glioblastoma. The…
Continue ReadingA Potential Treatment For Glioblastoma Has Shown Promising Interim Results in a Clinical Trial
The Boston-based biopharmaceutical company Berg LLC has announced that their experimental drug candidate BPM 31510 (ubidecarenone) has been awarded Orphan Drug designation by the US Food and Drug Administration (FDA)…
Continue ReadingA Drug Being Developed to Treat Epidermolysis Bullosa Has Been Granted Orphan Drug Status
The United States Food and Drug Administration (FDA) has granted the drug tafamidis Breakthrough Therapy designation for treating patients who have transthyretin cardiomyopathy. The full article can be read here,…
Continue ReadingA Potential Treatment for Transthyretin Cardiomyopathy Has Been Awarded Breakthrough Therapy Designation by the FDA
The United States Food and Drug Administration (FDA) has approved the label update for the medicine Taltz (ixekizumab) 80 mg/mL injection for psoriasis that affects the genital area. You can…
Continue ReadingTaltz Has Been Approved for Treating Psoriasis in the Genital Area
Two organisations, NeuroVive Pharmaceutical AB from Sweden and Yungjin Pharm Corporation based in South Korea, have announced encouraging initial results from a Phase I clinical trial of the experimental medicine…
Continue ReadingA Clinical Trial of an Experimental Treatment for Mitochondrial Disease Has Produced Promising Results
The companies Centogene and Orphazyme are collaborating on a clinical trial of the experimental small molecule therapy arimoclomol for Gaucher disease. The full article can be read here, at BusinessWire. Gaucher…
Continue ReadingThese Two Companies Are Collaborating on a Clinical Trial for Gaucher Disease
A drug called Hemlibra that is currently only approved for treating a subset of patients with haemophilia A has been found to be effective for wider use, reports Hemophilia News…
Continue ReadingA Haemophilia A Treatment has Been Shown to Help More Patients Than Previously Thought
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Sign Up For Our Patient Panel
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.